[Table_Title] 研究报告 Research Report 6 Apr 2025 安能物流（开曼） ANE (Cayman) (9956 HK) 量利高增，货重结构与效率持续优化 High Growth in Volume and Profit, with Optimization of Cargo Structure and Efficiency 骆雅丽 Yali Luo 虞楠 Nan Yu yl.luo@htisec.com nan.yu@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 安能物流发布 2024 年年报：2024 年，公司实现营业收入 115.76 亿元（人民币，下同），同比+16.7%，实现归母净 利润 7.50 亿元，同比+91.1%，实现经调整净利润 8.37 亿元，同比+64.2%。业绩符合预期。 点评 收入端：货重结构持续优化，增值服务需求增加。2024 年，公司货运总量增加至 14.1 百万吨，同比增长 ...

[Table_Title] 研究报告 Research Report 4 Apr 2025 国际工业+能源周报 Global Industrials + Energy 国际 AI 工业+能源周报(03/31-04/06)：SpaceX 拟投 18 亿美元扩建佛州星舰 设施，成功发射人类首次极地轨道载人航天任务 SpaceX to Invest $1.8 Billion to Expand Starship Facilities in Florida and Launches Human - Rated Mission in Polar Orbit 杨斌 Bin Yang 毛琼佩 Olivia Mao 杨钰其 Yuqi Yang Ella Ming bin.yang@htisec.com olivia.qp.mao@htisec.com yq.yang@htisec.com ella.yx.ming@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 核 ...

Investment Rating - The report maintains an "Outperform" rating for DPC Dash [2][6][13] Core Views - DPC Dash reported a revenue of RMB 4.31 billion for 2024, representing a year-on-year increase of 41% [3][12] - The company achieved a same-store sales growth (SSSG) of 2.5%, marking 30 consecutive quarters of positive growth [4][12] - The gross profit margin (GPM) stood at 72.9%, up 0.3 percentage points year-on-year, while the operating profit margin (OPM) was 14.5%, an increase of 0.7 percentage points [5][12] - Adjusted net profit reached RMB 131 million, with an adjusted net profit margin of 3.0%, up 2.7 percentage points year-on-year [5][12] Financial Performance Summary - Revenue projections for 2025-2027 are RMB 5.44 billion, RMB 7.03 billion, and RMB 8.78 billion, respectively, with year-on-year growth rates of 26%, 29%, and 25% [6][11] - Adjusted net profit forecasts for the same period are RMB 188 million, RMB 340 million, and RMB 492 million, with growth rates of 44%, 80%, and 45% respectively [6][11] - The company plans to open 300 new stores in 2025, following a net addition of 240 stores in 2024, bringing the total to 1,008 stores [4][12] Valuation and Target Price - The target price is set at HKD 125.9, reflecting a valuation of 2.5-3 times the price-to-sales (PS) ratio for 2025 [2][6][13] - The current market capitalization is approximately HKD 14.95 billion (USD 1.92 billion) [2][6]

Investment Rating - The report maintains an "Outperform" rating for Yum China Holdings [5][11]. Core Insights - Yum China Holdings reported a revenue of 11.30 billion USD for 2024, a 3% year-over-year increase, with an adjusted net profit of 911 million USD, up 8% year-over-year [2][11]. - In Q4 2024, revenue reached 2.60 billion USD, reflecting a 4% year-over-year growth, and adjusted net profit was 115 million USD, up 11% year-over-year [2][11]. - The company plans to add approximately 1,600 to 1,800 new stores in 2025, with capital expenditures estimated between 700 to 800 million USD [3][11]. Summary by Sections Financial Performance - For Q4 2024, KFC and Pizza Hut system sales grew by 5% and 3% respectively, with same-store sales declining by 1% and 2% [2][11]. - KFC's order volume increased by 3%, while average transaction value decreased by 4%; Pizza Hut's order volume rose by 9%, with a 10% drop in average transaction value [2][11]. - The total number of restaurants reached 16,395 by the end of 2024, with a net increase of 1,751 restaurants, representing a 12% annual growth [3][11]. Digital and Delivery Growth - By the end of Q4 2024, KFC and Pizza Hut had over 525 million members, contributing to 65% of sales [4][11]. - Digital orders accounted for 90% of restaurant income, totaling 9.60 billion USD for the year, while delivery sales grew by 14% year-over-year, making up 39% of restaurant income [4][11]. Cost Control and Efficiency - The report highlights improved cost control measures, with raw materials accounting for 31.9% of income (down 0.5 percentage points), staff costs at 28.2% (down 0.8 percentage points), and rent and other expenses at 27.6% (down 0.3 percentage points) [4][11]. - The restaurant profit margin for Q4 2024 was reported at 12.3%, an increase of 1.6 percentage points year-over-year [3][11]. Profit Forecast and Valuation - The forecast for net profit from 2025 to 2027 is 950 million USD, 1.01 billion USD, and 1.07 billion USD, with growth rates of 4.3%, 5.9%, and 6.6% respectively [5][11]. - The target price is set at 431.8 HKD per share based on a 22x PE ratio for 2025 [5][11].

Investment Rating - The report does not explicitly state an investment rating for China BlueChemical Core Views - The recurring net profit for 2024 decreased by 28.33% year-on-year, with total sales revenue of 11.946 billion yuan, down 8.40% year-on-year, and net profit of 1.071 billion yuan, down 55.02% year-on-year [2][3] - The decline in revenue is primarily attributed to fluctuations in the urea market, leading to a significant drop in sales prices [2][3] - The company plans to distribute a cash dividend of approximately 557 million yuan, with a dividend payout ratio of 51.98% and a dividend yield of 6.09% [2][3] Summary by Product - Urea sales revenue was 3.711 billion yuan, down 20.70% year-on-year, due to a decrease in sales price by 382.9 yuan per ton and a reduction in sales volume by 103,832 tons, with a gross profit margin of 19% [4] - Phosphate and compound fertilizers sales revenue was 2.687 billion yuan, down 0.70% year-on-year, with an increase in sales price by 67.1 yuan per ton but a decrease in sales volume by 22,605.8 tons, maintaining the same gross profit margin as the previous year [4] - Methanol sales revenue was 3.091 billion yuan, up 1.90% year-on-year, driven by an increase in sales price by 66.2 yuan per ton, despite a decrease in sales volume by 17,611.3 tons, with a gross profit margin of 27% [4] - Acrylonitrile series products sales revenue was 2.011 billion yuan, up 54.30% year-on-year, due to an increase in sales price by 738.1 yuan per ton and an increase in sales volume by 66,191.8 tons, with the gross profit margin turning positive [4] Strategic Developments - The company is expanding its phosphate rock resources through its subsidiary Hubei Dayukou Chemical Co., Ltd., which is constructing a mining project with an annual capacity of 1.6 million tons, expected to commence production in 2026 [5] - The company holds a 33.99% stake in Guizhou Jinlin Chemical Co., Ltd., which is expected to generate significant annual operating income and profit once its phosphate mine project is fully operational [5] - The company signed a memorandum of understanding with BASF to establish a Joint Laboratory for Advanced Green C1 Chemical Technology, focusing on sustainable and low-carbon solutions [6]

Investment Rating - The report maintains an "OUTPERFORM" rating for WuXi XDC Cayman, with a target price of HK$49.10, representing a potential upside of 47% from the current price of HK$41.90 [1][19]. Core Insights - WuXi XDC achieved robust growth in 2024, with revenue reaching RMB4.052 billion, a year-on-year increase of 90.8%. The gross margin improved to 30.6%, up 4.3 percentage points, and net profit attributable to shareholders surged 277.2% to RMB1.070 billion [4][12]. - The company secured 53 new integrated projects and 23 iCMC projects in 2024, supporting clients in submitting 30 IND applications and delivering over 300 GMP production batches [5][13]. - North America emerged as the fastest-growing region, with revenue from North American clients reaching RMB2.03 billion, a 138.3% increase year-on-year, accounting for 50.1% of total revenue [15]. Financial Performance - Revenue projections for WuXi XDC from 2025 to 2027 are RMB5.587 billion, RMB7.387 billion, and RMB9.462 billion, with year-on-year growth rates of 37.9%, 32.2%, and 28.1% respectively [7][18]. - Net profit attributable to shareholders is expected to be RMB1.342 billion, RMB1.818 billion, and RMB2.403 billion for the same period, with growth rates of 25%, 35%, and 32% respectively [10][18]. - The adjusted net profit is projected to be RMB1.550 billion, RMB2.010 billion, and RMB2.580 billion, with growth rates of 32%, 30%, and 28% [10][18]. Market Position and Strategy - By the end of 2024, WuXi XDC had a total backlog of RMB991 million, reflecting a 71% year-on-year growth, with new contract signings maintaining pace with this growth [16]. - The company plans to maintain high capital expenditures, with 2025 CAPEX projected to exceed RMB1.4 billion, focusing on expanding its global manufacturing footprint and technical capabilities [17].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 45.50 per share, corresponding to HKD 48.92 per share at a 0.93 exchange rate [7][10]. Core Insights - The company reported stable revenue of RMB 42.90 billion for 2024, with a slight year-on-year increase of 0.54%, and a net profit attributable to shareholders of RMB 12.12 billion, reflecting a 0.36% increase [3][10]. - Despite challenges, the company maintained its leading market share in packaged water, although revenue from this segment declined by 21.3% to RMB 15.95 billion due to external factors [3][10]. - The company is expected to recover in 2025 as it clarifies its position to the public and continues its strategic initiatives [3][10]. Financial Data and Forecasts - Total revenue and net profit forecasts for 2025-2027 are as follows: - 2025: Revenue of RMB 50.69 billion, net profit of RMB 14.57 billion, EPS of RMB 1.30 - 2026: Revenue of RMB 58.91 billion, net profit of RMB 16.95 billion, EPS of RMB 1.51 - 2027: Revenue of RMB 67.98 billion, net profit of RMB 19.83 billion, EPS of RMB 1.76 [2][10]. - The gross profit margin (GPM) decreased by 1.46 percentage points, leading to a 1.93% decline in gross profit [3][10]. Business Segment Performance - The packaged water segment remains under pressure but retains the highest market share in China, supported by strategic investments in water source facilities [3][10]. - The tea beverage segment showed strong growth, achieving revenue of RMB 16.75 billion, a year-on-year increase of 32.3% [4][10]. - Functional beverages and juice products also demonstrated resilience, with revenues of RMB 4.93 billion and RMB 4.08 billion, respectively, indicating ongoing product innovation and market demand [5][6][10].

Investment Rating - The report maintains an "OUTPERFORM" rating for Pop Mart International [2][9][17] Core Views - The company achieved record revenue and profit, with revenue expected to approach RMB 100 billion [1][3] - The company projects revenue growth of over 50% for 2025, with overseas revenue expected to exceed RMB 10 billion, reflecting a growth rate of over 100% [3][4] - The gross profit margin is anticipated to improve due to increased overseas revenue and effective supply chain cost control [3][4] Summary by Sections Financial Performance - In 2024, Pop Mart's revenue reached RMB 13 billion, a 107% year-on-year increase, with a gross profit margin of 66.8%, up 5.5 percentage points [3][16] - Adjusted net profit was RMB 3.4 billion, representing a 186% increase year-on-year, with an adjusted net profit margin of 26.1%, up 7.2 percentage points [3][16] - The company expects revenue for 2025 to be RMB 22.1 billion, with adjusted net profit projected at RMB 6.3 billion [9][17] Domestic Business - Domestic revenue was RMB 7.97 billion, a 52% year-on-year increase, with retail store revenue contributing RMB 3.83 billion, up 44% [4][16] - Online sales recovered with a 77% year-on-year increase, driven by new customer acquisition [4][16] - The total number of retail stores reached 401, with a net increase of 38 stores [4][16] International Business - International revenue surged to RMB 5.07 billion, a 375% year-on-year increase, with overseas revenue accounting for 39% of total revenue [5][16] - The company expanded its retail presence internationally, adding 50 new stores and entering five new markets [5][16] - The gross profit margin for international operations was 71.3%, exceeding domestic levels [5][16] IP Development and Innovation - The company reported that revenue from its major IPs accounted for 97.6% of total IP revenue, with significant growth in several key IPs [7][16] - Plush products emerged as a major revenue driver, with sales increasing over 12 times year-on-year [7][16] - Membership growth reached a historical high, with 46.08 million registered members contributing 92.7% of sales [7][16] Future Outlook - The company plans to open over 100 new stores in 2025 and enhance its brand strategy through flagship and themed stores [5][16] - Revenue projections for 2025-2027 are RMB 22.1 billion, RMB 33.7 billion, and RMB 46.2 billion, respectively, with adjusted net profits expected to grow correspondingly [9][17]

Investment Rating - The report maintains an "Outperform" rating for Sino Biopharmaceutical [2][11][17] Core Insights - The company achieved revenue of CNY 28.9 billion in FY24, reflecting a year-on-year growth of 10.2%, with a gross profit margin of 81.5% [3][14] - Innovative products are expected to drive double-digit revenue growth in FY25, particularly in oncology and surgery/analgesia segments [4][15] - The company plans to launch seven innovative products in FY25, including key candidates such as TQB3616 and Meloxicam [5][16] Financial Performance - FY24 revenue was CNY 28.9 billion, with a net profit of CNY 3.5 billion, marking a 50.1% increase year-on-year [3][14] - R&D expenses increased by 15.6% to CNY 5.1 billion, representing 17.6% of total revenue [3][14] - The company expects revenue to reach CNY 32.4 billion in FY25, a growth of 12.3% year-on-year [6][16] Product Segments - Revenue from innovative drugs reached CNY 12.1 billion, up 22% year-on-year, while generics contributed CNY 16.8 billion, growing 3% [4][15] - The oncology segment generated CNY 10.7 billion, driven by strong sales of key products [18] - The surgery/analgesia segment saw a revenue increase of 19% to CNY 4.5 billion, supported by the sales of Flurbiprofen Cataplasms [18] Future Outlook - The company anticipates significant contributions from new product launches and clinical data readouts in 2025 [5][16] - Management expects the liver diseases segment to introduce one innovative drug and five biosimilars/generics between 2025 and 2027 [18] - The report projects a target price of HKD 5.52 for the stock, based on a P/E ratio of 25.2x for 2025 [6][17]

Investment Rating - The report maintains an "Outperform" rating for the company, indicating an expected relative performance exceeding the benchmark index by over 10% in the next 12-18 months [2][8]. Core Insights - The company achieved a revenue of 40.87 billion RMB in 2024, representing a 33% year-over-year increase, with Q4 revenue reaching 16.11 billion RMB, up 23% year-over-year and 59% quarter-over-quarter [8]. - The net loss for 2024 was narrowed to 5.79 billion RMB, with Q4 net loss at 1.33 billion RMB, showing improvement [8]. - Vehicle sales revenue in Q4 was 14.67 billion RMB, up 20% year-over-year and 67% quarter-over-quarter, driven by increased deliveries of 92,000 units, which is a 52% year-over-year and 97% quarter-over-quarter increase [8]. - The company is expected to continue strong performance in 2025, with a forecast of 91,000-93,000 vehicle deliveries in Q1, representing a year-over-year increase of 317%-326% [8]. Financial Data and Forecast - Revenue projections for 2025, 2026, and 2027 are 90.83 billion RMB, 130.71 billion RMB, and 152.66 billion RMB respectively, with net profits expected to be -1.2 billion RMB, 2.9 billion RMB, and 6.5 billion RMB [2][8]. - The gross profit margin (GPM) improved to 14.3% in 2024, up 12.8 percentage points year-over-year, with Q4 GPM at 14.4% [8]. - The company plans to expand its global presence, targeting over 60 countries by the end of 2025, with a goal for overseas sales to account for 50% of total sales in the next 10 years [8]. Valuation - The report uses the Price-to-Sales (PS) method for valuation, estimating PS ratios of 1.8, 1.3, and 1.1 for 2025, 2026, and 2027 respectively [8]. - The target price is set at 103.90 HKD, based on a PS of 2.0 times for 2025 [8].